+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN)



Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN)



European Journal of Medical Research 9(8): 391-399



Advanced glycation end (AGE)-products are a complex group of compounds that have been implicated in diabetes related long-term complications. Up to the present only few data exist about serum levels of the AGE-proteins N-epsilon-Carboxymethyllysine (CML) and pentosidine in patients with diabetes mellitus. In the present 10-year, population-based trial of a selection-free cohort of patients with insulin-treated diabetes mellitus, serum CML and pentosidine levels were examined in correlation to the patients' quality of diabetes control and the prevalence of diabetes related long-term complications. Following the reunification of Germany in 1989 the health care system was decentralised. Up to 1994/95 the relative HbA1c (HbA1c/mean normal) of patients with type 1 diabetes increased (1.65 +/- 0.35 versus 1.52 +/- 0.31, p = 0.002). For patients with type 2 diabetes it remained constant (1.75 +/- 0.4 versus 1.78 +/- 0.31, p = 0.669). During the following period (from 1994/95 to 1999/2000) specialised diabetes care, structured treatment and teaching programmes (TTP), intensified insulin therapy and blood glucose self-monitoring for all patients were broadly implemented. This was accompanied by a substantial improvement in the relative HbA1c of both, patients with type 1 (1.48 +/- 0.3, p<0.0001), and insulin-treated type 2 diabetes mellitus (1.47 +/- 0.25, p<0.0001). During the same period the mean concentration of the AGE-product CML in the sera of patients with type 1 and insulin-treated type 2 diabetes decreased (type 1: 1994/95: 1158.1 +/- 410.0 ng/ml versus 1999/2000: 938.5 +/- 422.4 ng/ml, p<0.0001, type 2: 1994/94: 1244.7 +/- 1231.3 ng/ml versus 1999/2000: 970.9 +/- 458.6 ng/ml, p = 0.007). For pentosidine the same tendency was found for patients with type 1 diabetes (1994/95: 253.6 +/- 280.7 pmol/ml versus 1999/2000: 148.2 +/- 91.4 pmol/ml, p<0.0001). For patients with type 1 diabetes there was a positive correlation between the relative HbA1c-value calculated over the total follow-up period of 10 years and the CML-concentration in 1999/2000 (r = 0.405, p = 0.017). In 1999/2000 a reduced creatinine clearance (

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 049307832

Download citation: RISBibTeXText

PMID: 15337629


Related references

AGE-products N-epsilon-Carboxymethyllysine and pentosidine in patients with type 1 and insulin-treated type 2 diabetes mellitus Results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany. Diabetologia 45(Suppl. 2): A 355-A 356, 2002

Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN). Journal of Diabetes and its Complications 17(2): 90-97, 2003

Structured diabetes therapy and education improves the outcome of patients with insulin treated diabetes mellitus. The 10 year follow-up of a prospective, population-based survey on the quality of diabetes care (the JEVIN Trial). Experimental and Clinical Endocrinology & Diabetes 114(1): 18-27, 2006

The quality of life of patients with type 1 and type 2 diabetes mellitus and impact on quality of diabetes care JEVIN, a population-based survey. Diabetologia 44(Suppl. 1): A258, 2001

Results of the prospective, population-based survey of insulin treated patients with type 1 and type 2 diabetes mellitus Improvement of diabetes control and the management of arterial hypertension 1989/90-1999/2000. Diabetologia 46(Suppl. 2): A 348-A 349, 2003

Improvement of quality of life and metabolic control of patients with type-1- and insulin treated type-2-diabetes mellitus Results of a population-based 10 years follow up. Diabetologia 45(Suppl. 2): A 313, 2002

Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). European Journal of Medical Research 10(8): 339-344, 2005

Nepsilon -carboxymethyllysine and pentosidine in patients with type 1 and insulin-treated type 2 diabetes mellitus Results from a population-based survey. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 653A, 2002

Nutrition of insulin treated patients with diabetes mellitus in Germany Recommendations and reality The 10 year follow-up of a prospective, population-based survey. Diabetologia 45(Suppl. 2): A 270-A 271, 2002

Changes in Quality of Diabetes Care and Morbidity over 20 Years in People with Type 1 Diabetes and Long Diabetes Duration: The JEVIN Trial. Experimental and Clinical Endocrinology and Diabetes 125(2): 122-129, 2016

The JEVIN trial: a population-based survey on the quality of diabetes care in Germany: 1994/1995 compared to 1989/1990. Diabetologia 40(11): 1350-1357, 1997

Temporal trends in quality of primary care for patients with type 2 diabetes mellitus: A population-based retrospective cohort study after implementation of a quality improvement initiative. Diabetes/Metabolism Research and Reviews 34(2), 2017

Trends in the management of arterial hypertension in patients with type 1 and insulin-treated type 2 diabetes mellitus over a period of 10 years (1989/1990-1994/1995). Results of the JEVIN trial. Journal of Diabetes and Its Complications 20(5): 273-279, 2006

Improvement of the quality of diabetes care JEVIN, a population-based survey with 10-years-follow-up 1989/1990 - 1999/2000. Diabetologia 44(Suppl. 1): A247, 2001

Costs of therapy of insulin-treated patients with Diabetes mellitus in Germany. Results of the JEVIN trial. Medizinische Klinik 100(8): 453-461, 2005